Company to provide update on significant milestones and near-term plans, including its recent successful financing and agreements with Ottobock and CEAEINDHOVEN, the Netherlands, Nov. 12, 2024 (GLOBE ...
The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...
A trial involving one of Boston’s premier hospitals is laying ... urge a more cautious approach to assessment, say that ample scientific evidence shows that such treatments are beneficial ...
Deep Brain Stimulator MarketThe global deep brain stimulator market, valued at USD 1308.0 Million in 2024, is projected to grow steadily, reaching USD 2772.1 billion by 2034. With an anticipated CAGR ...
On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe ...
MARLBOROUGH, Mass. – Boston Scientific Corporation (NYSE: NYSE:BSX) today disclosed the primary endpoint results from its ACURATE IDE clinical trial, which assessed the ACURATE neo2™ Aortic Valve ...
The data were presented at Transcatheter Cardiovascular Therapeutics 2024, the annual scientific symposium of the Cardiovascular Research Foundation. This randomized trial evaluated the ACURATE ne ...
Inceptiv is a small device, implanted in the lower torso with leads to the spinal cord, that provides responsive counter-stimulation to relieve chronic pain. The device was approved by the FDA in ...
using spinal cord transcutaneous stimulation (scTS). This promising approach to enhance cardiovascular regulation addresses the challenges of unstable blood pressure and the accompanying ...